Drug intelligence / Profile preview

felcisetrag

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous

Overview

Felcisetrag is a potent and highly selective serotonin 5-HT4 receptor agonist developed as a prokinetic agent for the treatment of gastrointestinal motility disorders. By binding to and activating the 5-HT4 receptor (encoded by HTR4), felcisetrag enhances gastrointestinal motility, accelerates gastric emptying, and reduces colonic transit time. It has been investigated primarily for conditions such as gastroparesis (including diabetic and idiopathic forms), enteral feeding intolerance, postoperative gastrointestinal dysfunction, and other slow-transit disorders of the gut. Felcisetrag is administered intravenously and has demonstrated dose-proportional pharmacokinetics with good tolerability in clinical studies[1][2][3][5][6].

Other names: felcisetrag

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on felcisetrag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on felcisetrag.

Explore the full profile